癌症妇女代谢综合征危险因素与免疫组织化学特征的相关性。

IF 1.6 Q2 MEDICINE, GENERAL & INTERNAL
Hiva Danesh, Robab Anbiaei, Nasrin Ziamajidi, Maryam Farhadian, Zeinab Barartabar, Roghayeh Abbasalipourkabir
{"title":"癌症妇女代谢综合征危险因素与免疫组织化学特征的相关性。","authors":"Hiva Danesh,&nbsp;Robab Anbiaei,&nbsp;Nasrin Ziamajidi,&nbsp;Maryam Farhadian,&nbsp;Zeinab Barartabar,&nbsp;Roghayeh Abbasalipourkabir","doi":"10.30476/IJMS.2022.95039.2673","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The association between metabolic syndrome (MetS) and breast cancer may significantly impact the mortality and incidence of breast cancer. This study aimed to assess the association between MetS risk factors and immunohistochemical (IHC) profiles in women with breast cancer.</p><p><strong>Methods: </strong>This cross-sectional study used the medical records of 300 breast cancer patients with an average age of 53.11±12.97 years in the Chemotherapy and Radiation Therapy Clinic of Dr. Anbiai, Tehran, Iran (2020-2021). The cases were divided into five subgroups including luminal A, luminal B (HER-2<sup>-</sup>), luminal B (HER-2<sup>+</sup>), HER-2 overexpressing, and triple negative.</p><p><strong>Results: </strong>There was no difference in the prognostic indicators between the presence and absence of MetS in women with breast cancer. A higher proportion of luminal A tumors (39.3%), luminal B (HER-2<sup>+</sup>) (25%), triple-negative (17%), luminal B (HER-2<sup>-</sup>) (10.7%), HER-2 overexpression (8%) was observed in women with MetS than those without MetS. Multivariate logistic regression analysis showed that patients with MetS had a 41% higher chance of developing luminal A than those without MetS, and patients with a BMI≥30 Kg/m<sup>2</sup> had an 80% higher chance of developing luminal B (HER-2<sup>+</sup>) than those with a BMI<30 Kg/m<sup>2</sup>. Moreover, women with a waist circumference higher than 88 cm had a 14 % lower chance of developing Luminal B (HER-2<sup>+</sup>) than those with a waist circumference less than 88 cm.</p><p><strong>Conclusion: </strong>There was no difference in prognostic indicators and IHC profile in patients with and without MetS.</p>","PeriodicalId":14510,"journal":{"name":"Iranian Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/43/IJMS-48-456.PMC10541543.pdf","citationCount":"0","resultStr":"{\"title\":\"Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer.\",\"authors\":\"Hiva Danesh,&nbsp;Robab Anbiaei,&nbsp;Nasrin Ziamajidi,&nbsp;Maryam Farhadian,&nbsp;Zeinab Barartabar,&nbsp;Roghayeh Abbasalipourkabir\",\"doi\":\"10.30476/IJMS.2022.95039.2673\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The association between metabolic syndrome (MetS) and breast cancer may significantly impact the mortality and incidence of breast cancer. This study aimed to assess the association between MetS risk factors and immunohistochemical (IHC) profiles in women with breast cancer.</p><p><strong>Methods: </strong>This cross-sectional study used the medical records of 300 breast cancer patients with an average age of 53.11±12.97 years in the Chemotherapy and Radiation Therapy Clinic of Dr. Anbiai, Tehran, Iran (2020-2021). The cases were divided into five subgroups including luminal A, luminal B (HER-2<sup>-</sup>), luminal B (HER-2<sup>+</sup>), HER-2 overexpressing, and triple negative.</p><p><strong>Results: </strong>There was no difference in the prognostic indicators between the presence and absence of MetS in women with breast cancer. A higher proportion of luminal A tumors (39.3%), luminal B (HER-2<sup>+</sup>) (25%), triple-negative (17%), luminal B (HER-2<sup>-</sup>) (10.7%), HER-2 overexpression (8%) was observed in women with MetS than those without MetS. Multivariate logistic regression analysis showed that patients with MetS had a 41% higher chance of developing luminal A than those without MetS, and patients with a BMI≥30 Kg/m<sup>2</sup> had an 80% higher chance of developing luminal B (HER-2<sup>+</sup>) than those with a BMI<30 Kg/m<sup>2</sup>. Moreover, women with a waist circumference higher than 88 cm had a 14 % lower chance of developing Luminal B (HER-2<sup>+</sup>) than those with a waist circumference less than 88 cm.</p><p><strong>Conclusion: </strong>There was no difference in prognostic indicators and IHC profile in patients with and without MetS.</p>\",\"PeriodicalId\":14510,\"journal\":{\"name\":\"Iranian Journal of Medical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/43/IJMS-48-456.PMC10541543.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30476/IJMS.2022.95039.2673\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/IJMS.2022.95039.2673","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:代谢综合征(MetS)与乳腺癌症之间的相关性可能显著影响癌症的死亡率和发病率。本研究旨在评估癌症妇女的MetS危险因素与免疫组织化学(IHC)谱之间的关系。方法:本横断面研究使用了伊朗德黑兰Anbiai医生化疗和放射治疗诊所(2020-2021年)300名平均年龄为53.11±12.97岁的癌症患者的医疗记录。将这些病例分为五个亚组,包括管腔A、管腔B(HER-2-)、腔B(HER-2+)、HER-2过表达和三阴性。结果:癌症妇女有无MetS的预后指标没有差异。在患有MetS的女性中,观察到管腔A肿瘤(39.3%)、管腔B肿瘤(HER-2+)(25%)、三阴性(17%)、管腔B肿瘤(HER-2-)(10.7%)和HER-2过表达(8%)的比例高于未患有MetS的女性。多因素logistic回归分析显示,患有代谢综合征的患者发生管腔a的几率比没有代谢综合征患者高41%,BMI≥30 Kg/m2的患者患管腔B(HER-2+)的几率比患有BMI2的患者高80%。此外,腰围大于88 cm的女性患Luminal B(HER-2+)的几率比腰围小于88 cm的患者低14%。结论:MetS患者和非MetS患者的预后指标和IHC特征没有差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer.

Background: The association between metabolic syndrome (MetS) and breast cancer may significantly impact the mortality and incidence of breast cancer. This study aimed to assess the association between MetS risk factors and immunohistochemical (IHC) profiles in women with breast cancer.

Methods: This cross-sectional study used the medical records of 300 breast cancer patients with an average age of 53.11±12.97 years in the Chemotherapy and Radiation Therapy Clinic of Dr. Anbiai, Tehran, Iran (2020-2021). The cases were divided into five subgroups including luminal A, luminal B (HER-2-), luminal B (HER-2+), HER-2 overexpressing, and triple negative.

Results: There was no difference in the prognostic indicators between the presence and absence of MetS in women with breast cancer. A higher proportion of luminal A tumors (39.3%), luminal B (HER-2+) (25%), triple-negative (17%), luminal B (HER-2-) (10.7%), HER-2 overexpression (8%) was observed in women with MetS than those without MetS. Multivariate logistic regression analysis showed that patients with MetS had a 41% higher chance of developing luminal A than those without MetS, and patients with a BMI≥30 Kg/m2 had an 80% higher chance of developing luminal B (HER-2+) than those with a BMI<30 Kg/m2. Moreover, women with a waist circumference higher than 88 cm had a 14 % lower chance of developing Luminal B (HER-2+) than those with a waist circumference less than 88 cm.

Conclusion: There was no difference in prognostic indicators and IHC profile in patients with and without MetS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Iranian Journal of Medical Sciences
Iranian Journal of Medical Sciences MEDICINE, GENERAL & INTERNAL-
CiteScore
3.20
自引率
0.00%
发文量
84
审稿时长
12 weeks
期刊介绍: The Iranian Journal of Medical Sciences (IJMS) is an international quarterly biomedical publication, which is sponsored by Shiraz University of Medical Sciences. The IJMS intends to provide a scientific medium of com­muni­cation for researchers throughout the globe. The journal welcomes original clinical articles as well as clinically oriented basic science re­search experiences on prevalent diseases in the region and analysis of various regional problems.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信